Uploaded December 2025 | Updated November 2026, 1 day ago
The rising prevalence of sexually transmitted infections (STIs) and antimicrobial resistance (AMR) presents significant challenges to public health, necessitating robust policies and advanced diagnostic strategies. This presentation will explore the intersection of STI and AMR trends, emphasizing their impact on public health initiatives and the critical role of diagnostic tools in identifying key resistance mutations. We will highlight recent advancements in diagnostic technologies that enable accurate and timely detection of STIs and AMR, improving clinical decision-making and potential patient outcomes. Additionally, key data and insights will be shared to underscore the importance of refining diagnostic strategies, particularly addressing the underdiagnosis of Mycoplasma genitalium (Mgen) and its clinical implications. By bridging diagnostic innovation with public health policy, we aim to support a more effective response to the evolving STI and AMR landscape.
Learning Objectives
Explore how STI and AMR trends are influencing public health policies and the role of diagnostic tools in mitigating these issues, including identifying the necessary mutations for antimicrobial resistance (AMR) that need to be tested for.
Showcase advancements in diagnostic technologies that support accurate and timely detection of STIs and AMR.
Share key data and insights, highlighting implications for diagnostic strategies and treatment pathways, including addressing the underdiagnosis of Mycoplasma genitalium (Mgen) and its clinical implications.
The rising prevalence of sexually transmitted infections (STIs) and antimicrobial resistance (AMR) presents significant challenges to public health, necessitating robust policies and advanced diagnostic strategies. This presentation will explore the intersection of STI and AMR trends, emphasizing their impact on public health initiatives and the critical role of diagnostic tools in identifying key resistance mutations. We will highlight recent advancements in diagnostic technologies that enable accurate and timely detection of STIs and AMR, improving clinical decision-making and potential patient outcomes. Additionally, key data and insights will be shared to underscore the importance of refining diagnostic strategies, particularly addressing the underdiagnosis of Mycoplasma genitalium (Mgen) and its clinical implications. By bridging diagnostic innovation with public health policy, we aim to support a more effective response to the evolving STI and AMR landscape.
Learning Objectives
Explore how STI and AMR trends are influencing public health policies and the role of diagnostic tools in mitigating these issues, including identifying the necessary mutations for antimicrobial resistance (AMR) that need to be tested for.
Showcase advancements in diagnostic technologies that support accurate and timely detection of STIs and AMR.
Share key data and insights, highlighting implications for diagnostic strategies and treatment pathways, including addressing the underdiagnosis of Mycoplasma genitalium (Mgen) and its clinical implications.






![Evolving Respiratory Viral Testing in the Post-Pandemic Era: Clinical and Lab Perspectives
In the post–COVID-19 pandemic era, the role of respiratory viral testing continues to evolve. Explore the clinical value of testing and what positive results mean for patient management and treatment decisions, all while connecting clinical and laboratory insights to demonstrate how optimized respiratory testing can support better decision-making and efficiency in today’s healthcare environment.
Disclaimer: Waters Corporation has acquired BD [Biosciences/Diagnostic Solutions]. BD remains the legal manufacturer until all required regulatory transfers are complete. Learn more: www.waters.com/bdtransaction (https://www.waters.com/bdtransaction) Evolving Respiratory Viral Testing in the Post-Pandemic Era: Clinical and Lab Perspectives](https://i.ytimg.com/vi/QIWA5SrLomA/mqdefault.jpg)



